received a not approvable letter from the Food and Drug Administration for a new injection form of the schizophrenia treatment Zyprexa. Shares of Lilly were down 1.9% at $50.85 Thursday. Zyprexa, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback